Jonathan Fleming Email & Phone Number

Currently the Chairman of the Board of six early stage life science companies, teach a course on life science strategy at MIT and invest in early stage companies through my family office Pimlico Pond Investments. Since 2018 Mr. Fleming has been Executive Chairman of Enclear Therapies, which is developing therapies to remove toxic proteins from the CSF of patients with ALS, PSP and Alzheimer's Disease. From 2015 to 2018 Mr. Fleming was President and CEO of Q-State Biosciences. From 1996 to 2015, Mr. Fleming was the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, MA. Mr. Fleming has been in the investment business for more than 34 years, starting and financing growth companies in the United States, Europe, Israel and Asia. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers. Mr. Fleming holds a Master's degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor's degree in Political Science from the University of California, Berkeley.

Listed skills include Venture Capital, Start Ups, Corporate Development, Entrepreneurship, and 25 others.